Second European Medicines Agency workshop on neurodegenerative diseases: focus on dementia

• Date:
  Tuesday, 12 February 2008
• Location:
  European Medicines Agency, Amsterdam, the Netherlands

This workshop is involving a panel of European experts actively involved in clinical and non-clinical research into dementia. The United States Food and Drug Administration is contributing to the debate on the current regulatory requirements in terms of development of new medicines for dementia.The workshop is expected to allow the participants to convey their respective views and identify a common ground of enrichment between academia, patients, healthcare professionals, industry and regulators.The elements originating during the discussion will not constitute a formal specific advice on

Documents

Agenda - Second EMEA Workshop on Neurodegenerative Diseases, 'Focus on Dementia'

Reference Number: EMEA/48200/2008 Rev. 1.5

Second EMEA Workshop on Neurodegenerative Diseases, 'Focus on Dementia' -Brief Report & Presentations

Reference Number: EMEA/87024/2008

Alzheimer's disease - Target population and development of biomarkers - Harald Hampel

Primary Endpoints in 'Alzheimer's Dementia' - Karl Broich

Neuroimaging in trials in AD - Nick Fox

Overlap between VaD and AD: An epidemiological perspective - Miia Kivipelto

Vascular Dementia or Dementia with Cerebro-Vascular Disease: Changes in Concepts - Jean-Marc Orgogozo

Lewy body dementias - Target population and specific end points - Ian McKeith

Frontotemporal Dementia: More than an exclusion diagnosis? - Alessandro Padovani

'Neuroprotection' in Neurodegenerative disorders. Towards a change in the paradigm?

Received Comments to the Draft Guideline (Rev1) for treatment of Alzheimer's disease and other dementias - Susanna Del Signore